Anteris Technologies Global Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
31.4%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$1.19next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Corporate Update | 15 Nov 2026 |
Monitoring Framework
Key Performance Indicators
PARADIGM Trial Patient Enrollment QuarterlyTarget: Complete enrollment for global pivotal trial
Cash and Cash Equivalents Quarterly283.2MTarget: Fund operations through pivotal trial and regulatory submission
Quarterly Net Sales Quarterly500KTarget: Pre-commercialization baseline
Watch Items
- U.S. Site Activation and Patient Recruitment for PARADIGM TrialTrigger: Slower-than-expected enrollment or delays in site activationAction: Increase clinical field support and optimize screening protocols
- Cash Burn Rate and ATM UtilizationTrigger: Quarterly cash burn exceeding $35 millionAction: Evaluate strategic pacing of R&D and selectively utilize the $250M ATM facility
Research as of 20 Jun 2026